Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tirasemtiv in amyotrophic lateral sclerosis
NL-OMON44882Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Tirasemtiv with Placebo (2 arms). Primary endpoint: Effect of tirasemtiv versus placebo on respiratory function. Started Apr 2016; status: active, not recruiting.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON44882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44882.